Core Viewpoint - Antu Biology has received a medical device registration certificate from the Henan Provincial Drug Administration for products including the "Interleukin-4 Test Kit" [1] Company Summary - Antu Biology's revenue composition for the year 2024 is projected to be 98.17% from in vitro diagnostics and 1.83% from other businesses [1] - As of the report, Antu Biology has a market capitalization of 21 billion yuan [1]

Core Viewpoint - Antu Bio and its wholly-owned subsidiary Antu Instruments have received 18 medical device registration certificates from the Henan Provincial Drug Administration, enhancing the company's product portfolio [1] Group 1: Company Developments - Antu Bio obtained 17 registration certificates, while Antu Instruments received 1 certificate, which includes products such as interleukin-4 testing kits and prenatal screening risk calculation software [1] - The registration certificates are valid for 5 years, indicating a long-term potential for product sales [1] Group 2: Market Context - Some domestic and international manufacturers have already obtained similar product registration certificates, suggesting a competitive landscape [1] - The short-term impact on the company's performance is expected to be minimal, and future sales performance of the new products remains uncertain [1]